SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

BRIEF-FDA Grants Genfit’s GNS561 Orphan Drug Designation

BRIEF-FDA Grants Genfit’s GNS561 Orphan Drug Designation

Reuters · 09/13/2022 16:14
BRIEF-FDA Grants Genfit’s GNS561 Orphan Drug Designation

- Genfit SA GNFT.PA:

  • FDA GRANTS GENFIT’S GNS561 ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF CHOLANGIOCARCINOMA

  • GENFIT SA- A PHASE 2 TRIAL IS EXPECTED TO START IN Q4 2022, WITH A FIRST PATIENT VISIT EXPECTED IN Q1 2023

Source text for Eikon: ID:

Further company coverage: GNFT.PA


((Reuters.Briefs@thomsonreuters.com;))